Allakos — Technical Presentation (May 2019)
48 slides from Allakos's technical presentation, May 7, 2019
Slide 1: Phase 1b SAC Results
Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Phase 1b SAC Results May 7, 2019 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos” or the “Company”); the generation of future value; business strat
Slide 3: Agenda
Agenda Robert Alexander, PhD Introductions AK002 5:00 – 5:15 PM Henrik Rasmussen, MD PhD Review of Clinical Program 5:15 – 5:20 PM C. Stephen Foster, MD & Stephen Anesi, MD Overview of Ocular Allergy AK002 in Severe Allergic Conjunctivitis Phase 1b Study 5:20 – 6:00 PM Q&A 6:00 – 6:20 PM
Slide 4: Introduction
Introduction Robert Alexander, PhD CEO – Allakos
Slide 5: Executive Summary
Executive Summary Clinical stage company focused on the development of AK002, an anti-Siglec-8 mAb Lead indication is Eosinophilic Gastritis and/or Gastroenteritis Phase 2 study results expected July/August 2019 Recently reported AK002 clinical activity Rapid depletion of blood eosinophils in health
Slide 6: Mast Cells and Eosinophils: Effector Cells Central to Inflammatory Responses
Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines
Slide 7: AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils
AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast Cell Eosinophil Inflammatory Response AK002 Inhibition Mast Cell Eosinophil Inhibition ADCC/Apoptosis AK002
Slide 8: Mast Cells and Eosinophils are Key Drivers of Atopic & Inflammatory Disease
Mast Cells and Eosinophils are Key Drivers of Atopic & Inflammatory Disease T Cell B Cell Activated B Cell Mast Cell IgE Activation and Recruitment of Other Immune Cells and Tissue Inflammation Macrophage Eosinophil Neutrophil Allergens Smooth Muscle Neuron Epithelium ACUTE AND CHRONIC INFLAMMATION
Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases
Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Gastroenteritis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTES
Slide 10: AK002 Clinical Development Overview
AK002 Clinical Development Overview Henrik Rasmussen, MD PhD CMO – Allakos
Slide 11: Current AK002 Development Status
AK002 Preclinical Phase 1 Phase 2 Data Expected Eosinophilic Gastritis July/August 2019 Chronic Urticaria Presented Q1 2019 Indolent Systemic Mastocytosis Presented Q1 2019 Severe Allergic Conjunctivitis Presented Today Current AK002 Development Status
Slide 12: AK002 Clinical Data to Date
AK002 Clinical Data to Date Key Findings Healthy Volunteers Rapid depletion of eosinophils Dose-dependent duration of eosinophil depletion Chronic Urticaria High response rates in multiple forms of antihistamine-resistant chronic urticaria, including omalizumab-refractory and inducible urticaria Ind
Slide 13: AK002 Safety Summary
AK002 Safety Summary No adverse findings in short- and long-term animal toxicity studies PRECLINICAL Approximately 180 subjects exposed to drug in clinical studies Generally well-tolerated Mild to moderate infusion reactions (flushing, feeling of warmth, headache, nausea, or dizziness) consistent wi
Slide 14: Severe Allergic Conjunctival Disease Phase 1b Study
Severe Allergic Conjunctival Disease Phase 1b Study Design Key Endpoints Status Open-label, pilot study 30 patients – 3 cohorts Atopic keratoconjunctivitis Vernal keratoconjunctivitis Perennial allergic conjunctivitis Dosed once monthly for 6 months 0.3 mg/kg starting dose, followed by 1.0 mg/kg the
Slide 15: C. Stephen Foster, MD and Stephen Anesi, MD
C. Stephen Foster, MD and Stephen Anesi, MD C. Stephen Foster, MD - Principal Investigator Founder and president of MERSI Professor, Ophthalmology & Adjunct Professor, Allergy & Immunology, Harvard Developed standard of care in treating uveitis/ocular inflammatory diseases Currently serves on >10 co
Slide 16: Phase 1b: AK002 in Patients with Severe Allergic Conjunctivitis
Phase 1b: AK002 in Patients with Severe Allergic Conjunctivitis C. Stephen Foster, MD Stephen Anesi, MD
Slide 17: AKC, PAC, & VKC are Severe Forms of Allergic Conjunctivitis
AKC, PAC, & VKC are Severe Forms of Allergic Conjunctivitis CLINICAL FEATURES IMPACT Symptoms Extreme Itching, Photophobia, Pain, Sensation of Foreign Body, Burning, Watering, Mucous Discharge Poor Quality of Life Signs Redness (Hyperemia), Swelling (Chemosis, Periorbital Edema), Tarsal Papillae, Ci
Slide 18: Severe Allergic Conjunctivitis
Severe Allergic Conjunctivitis Giant Papillae Corneal Ulcer (Vision Loss) Redness, Chemosis Photophobia, Watering, Periorbital Swelling
Slide 19: Immune Cells Involved in Allergic Conjunctivitis
Perennial Allergic Conjunctivitis (PAC) Vernal Keratoconjunctivitis (VKC) Atopic Keratoconjunctivitis (AKC) Mast Cells +++ +++ ++ Eosinophils ++ ++ +++ T and B cells + ++ +++ Fibroblasts ++ ++ Immune Cells Involved in Allergic Conjunctivitis Mast cells and eosinophils are key effector cells in aller
Slide 20: Limitations of Current Treatment Options
Limitations of Current Treatment Options Antihistamines / Mast Cell Stabilizers Require frequent dosing (up to 4 times per day) Typically ineffective in severe cases Ocular Topical Steroids Associated with multiple adverse effects, including cataracts and glaucoma Chronic, long-term use significantl
Slide 21: US Prevalence of Severe Allergic Conjunctivitis
US Prevalence of Severe Allergic Conjunctivitis US population experiencing Ocular Allergy Symptoms ~130 Million1 ~7.4 Million2 Diagnosed Allergic Conjunctivitis patients ~6% visit a physician for their condition (1) 40% of US population, Singh et al. J Allergy Clin Immunol. 2010 and Bielory et al. A
Slide 22: Severe Allergic Conjunctivitis – Unmet Need
Severe Allergic Conjunctivitis – Unmet Need ~120,000 patients in the US have antihistamine-refractory severe allergic conjunctivitis Significant disease burden, which can lead to blindness There are no safe chronic treatment options available
Slide 23: Severe Allergic Conjunctival Disease Phase 1b Study
Severe Allergic Conjunctival Disease Phase 1b Study Design Key Endpoints Status Open-label, pilot study 30 patients – 3 cohorts Atopic keratoconjunctivitis Vernal keratoconjunctivitis Perennial allergic conjunctivitis Dosed once monthly for 6 months 0.3 mg/kg starting dose, followed by 1.0 mg/kg the
Slide 24: Baseline Characteristics
Baseline Characteristics (1)By medical history AKC (N=13) VKC (N=1) PAC (N=16) Total (N=30) Age, Median (Range) 50 (23-72) 25 55 (29-79) 52 (23-79) Female 38% 0 63% 50% Age of AC Onset, Median (Range) 36 (7-72) 12 46 (19-69) 43 (7-72) Years with AC, Median (Range) 6 (0-38) 13 4 (0-19) 6 (0-38) Atopi
Slide 25: AK002 Clinical Activity Measured by PRO & Investigator Assessments
AK002 Clinical Activity Measured by PRO & Investigator Assessments Daily patient questionnaire Total ACS (0 – 50 point scale): Itching (0-10) Light sensitivity (0-10) Eye pain (0-10) Foreign body sensation (0-10) Watering eyes (0-10) Monthly investigator assessment Total OSS (0 – 13 point scale): It
Slide 26: Improvements in Allergic Conjunctivitis Signs & Symptoms
Improvements in Allergic Conjunctivitis Signs & Symptoms Median Total ACS Baseline Weeks 21-22 Median Total OSS Baseline Day 140 -71% -78% Patient Reported Investigator Assessment All Subjects (n=29)
Slide 27: Substantial Improvements in Multiple Forms of Severe AC
Substantial Improvements in Multiple Forms of Severe AC Median Total ACS AKC (n=13) Baseline Weeks 21-22 VKC (n=1) PAC (n=15) All Subjects (n=29) Baseline Weeks 21-22 Baseline Weeks 21-22 Baseline Weeks 21-22 -74% -87% -71% -78%
Slide 28: Consistent Improvements Across Signs & Symptoms
Consistent Improvements Across Signs & Symptoms Symptom Median % Δ from BL to Wk 21-22 Allergic Conjunctivitis Symptom (ACS) Patient Reported - Daily Itching -75% Light Sensitivity -57% Eye Pain -75% Foreign Body Sensation -80% Watering Eyes -76% Symptoms & Signs Median % Δ from BL to Day 140 Ocular
Slide 29: Substantial Improvement in Atopic Comorbidities
Substantial Improvement in Atopic Comorbidities Atopic Dermatitis (n=11) Baseline Weeks 21-22 -65% Asthma (n=9) Baseline Weeks 21-22 Rhinitis (n=11) Baseline Weeks 21-22 -72% -69% Median Symptom Score
Slide 30: Severe Allergic Conjunctivitis Phase 1b: Safety Summary
Severe Allergic Conjunctivitis Phase 1b: Safety Summary Generally very well-tolerated No drug-related Serious Adverse Events Most common adverse event was mild to moderate infusion-related reactions (IRRs; flushing, feeling of warmth, headache, nausea, or dizziness) 16.7% IRRs rate on first infusion
Slide 31: Patient Case Studies
Patient Case Studies C. Stephen Foster, MD Stephen Anesi, MD
Slide 32: Case Study 1: AKC with Comorbid Atopic Dermatitis & Rhinitis
Case Study 1: AKC with Comorbid Atopic Dermatitis & Rhinitis Medical History 27 year-old male with severe AKC, atopic dermatitis, and rhinitis Baseline normal peripheral blood eosinophils (190 eos/µL) Suffered from severe symptoms despite treatment Itching, foreign body sensation, and watering Hyper
Slide 33: Case Study 1: Improvement in Ocular Symptoms
Case Study 1: Improvement in Ocular Symptoms 99% reduction in Total ACS Watering Foreign Body Eye Pain Light Sensitivity Itching Total ACS Month 1 Month 2 Month 3 Month 4 Month 5 Weeks 21-22
Slide 34: Case Study 1: Improvement in Ocular Signs and Symptoms and Comorbidities
Case Study 1: Improvement in Ocular Signs and Symptoms and Comorbid Atopic Dermatitis and Rhinitis Total ACS Baseline Weeks 21-22 Total OSS -100% Baseline Day 140 Atopic Dermatitis Baseline Weeks 21-22 Rhinitis Baseline Weeks 21-22 -99% -82% -100% Symptom Score
Slide 35: Case Study 1: Reversal of Neovascular and Inflammatory Changes
Case Study 1: Reversal of Neovascular and Inflammatory Changes Prior to AK002 After 3 Doses of AK002
Slide 36: Case Study 2: AKC with Comorbid Atopic Dermatitis & Asthma
Case Study 2: AKC with Comorbid Atopic Dermatitis & Asthma Medical History 49 year-old male with severe AKC, atopic dermatitis, and asthma Baseline high peripheral blood eosinophils (1350 eos/µL) Suffered from severe symptoms despite treatment Photophobia, conjunctival hyperemia, and chemosis Perior
Slide 37: Case Study 2: Improvement in Ocular Symptoms
Case Study 2: Improvement in Ocular Symptoms 97% reduction in Total ACS Watering Foreign Body Eye Pain Light Sensitivity Itching Total ACS Month 1 Month 2 Month 3 Month 4 Month 5 Weeks 21-22
Slide 38: Case Study 2: Improvement in Ocular Signs and Symptoms and Comorbidities
Case Study 2: Improvement in Ocular Signs and Symptoms and Comorbid Atopic Dermatitis and Asthma Total ACS Baseline Weeks 21-22 Total OSS -82% Baseline Day 140 Atopic Dermatitis Baseline Weeks 21-22 Asthma Baseline Weeks 21-22 -97% -36% -78% Symptom Score
Slide 39: Case Study 2: Substantial Clinical Improvements
Case Study 2: Substantial Clinical Improvements Prior to AK002 After 3 Doses of AK002
Slide 40: Case Study 3: AKC with Comorbid Atopic Dermatitis, Asthma, and Rhinitis
Case Study 3: AKC with Comorbid Atopic Dermatitis, Asthma, and Rhinitis Medical History 53 year-old male with AKC, atopic dermatitis, asthma, and rhinitis Baseline normal peripheral blood eosinophils (120 eos/µL) Suffered from severe symptoms despite treatment Itching, photophobia, foreign body sens
Slide 41: Case Study 3: Improvements in Ocular Signs, Symptoms and Comorbidities
Case Study 3: Improvements in Ocular Signs and Symptoms and Comorbid Atopic Dermatitis, Asthma, and Rhinitis Total ACS Baseline Weeks 21-22 Atopic Dermatitis -67% Baseline Weeks 21-22 Asthma Baseline Weeks 21-22 Rhinitis Baseline Weeks 21-22 -88% -82% -96% Symptom Score
Slide 42: Case Study 4: AKC w/ Comorbid Esophagitis, Gastritis, Duodenitis, Urticaria
Case Study 4: AKC w/ Comorbid Esophagitis, Gastritis, Duodenitis, Urticaria Medical History 45 year old female with severe AKC, GI disease, and chronic urticaria Baseline normal peripheral blood eosinophils (160 eos/µL) Suffered from severe symptoms despite treatment Itching, photophobia, discomfort
Slide 43: Case Study 4: Improvement in Ocular Symptoms
Case Study 4: Improvement in Ocular Symptoms Total OSS Watering Foreign Body Eye Pain Light Sensitivity Itching Total ACS 99% reduction in Total ACS 100% reduction in Total OSS Month 1 Month 2 Month 3 Month 4 Month 5 Weeks 21-22
Slide 44: Case Study 4: Improvements in Ocular Signs and Symptoms
Case Study 4: Improvements in Ocular Signs and Symptoms Total ACS Baseline Weeks 21-22 Total OSS Baseline Day 140 -100% -99% Patient Reported Investigator Assessment Case Study 4: AKC Patient
Slide 45: Summary
Summary AK002 demonstrated clinical activity in severe allergic conjunctivitis AK002 is a targeted therapy that may represent a novel alternative to chronic steroid use Results suggest significant activity in systemic atopic comorbidities such as atopic dermatitis, asthma, and rhinitis
Slide 46: Executive Summary
Executive Summary Clinical stage company focused on the development of AK002, an anti-Siglec-8 mAb Lead indication is Eosinophilic Gastritis and/or Gastroenteritis Phase 2 study results expected July/August 2019 Recently reported AK002 clinical activity Rapid depletion of blood eosinophils in health
Slide 47: Q&A
Q&A
Slide 48: Thank you
Thank you